Literature DB >> 6087513

Ketoconazole in the treatment of eumycetoma due to Madurella mycetomii.

E S Mahgoub, S A Gumaa.   

Abstract

Eumycetoma is, at present, treated only by surgery which is amputation at times and mutilating excision at others. Surgical treatment is often followed by local, or rarely distant recurrence to regional lymph nodes and surrounding tissue. The results of the clinical trial with ketoconazole reported in this paper show that five of 13 patients were completely cured and four improved. It is worth noting that the daily dose for those cured was 400 or 300 mg while those who improved were on only 200 mg/day.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6087513     DOI: 10.1016/0035-9203(84)90126-3

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  24 in total

1.  Case 5--a 38-year-old man presented to Kijabe Mission Hospital with a swollen, draining right foot.

Authors:  Jon F Fielder; Tobias Otieno; David Solfelt
Journal:  MedGenMed       Date:  2004-04-27

2.  Madura foot: a surgical cure.

Authors:  R Visvanathan
Journal:  BMJ       Date:  1991-10-19

3.  In vitro interaction of currently used azoles with terbinafine against Madurella mycetomatis.

Authors:  Sarah Abdalla Ahmed; Wendy Kloezen; Ahmed H Fahal; G Sybren de Hoog; Wendy W J van de Sande
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

4.  Subcutaneous fungal infections.

Authors:  Ricardo M La Hoz; John W Baddley
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

5.  Eumycetoma of the hand caused by Leptosphaeria tompkinsii and refractory to medical therapy with voriconazole.

Authors:  Katharine E Cartwright; Tristan W Clark; Abid M Hussain; Martin Wiselka; Andrew Borman; Elizabeth M Johnson
Journal:  Mycopathologia       Date:  2011-05-13       Impact factor: 2.574

6.  Testing of the in vitro susceptibilities of Madurella mycetomatis to six antifungal agents by using the Sensititre system in comparison with a viability-based 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5- [(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay and a modified NCCLS method.

Authors:  Wendy W J van de Sande; Ad Luijendijk; Abdalla O A Ahmed; Irma A J M Bakker-Woudenberg; Alex van Belkum
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

7.  Ketoconazole: a reappraisal.

Authors:  R J Hay
Journal:  Br Med J (Clin Res Ed)       Date:  1985-01-26

8.  Pleurostomophora ochracea, a novel agent of human eumycetoma with yellow grains.

Authors:  Najwa A Mhmoud; Sarah Abdalla Ahmed; Ahmed H Fahal; G Sybren de Hoog; A H G Gerrits van den Ende; Wendy W J van de Sande
Journal:  J Clin Microbiol       Date:  2012-07-03       Impact factor: 5.948

Review 9.  Actinomycetoma-the welsh regimen in a rural Indian scenario.

Authors:  Saumya Mathews; Raviraj Jadhav; Ali Reza; Tanweer Karim
Journal:  Indian J Surg       Date:  2012-05-01       Impact factor: 0.656

10.  In vitro susceptibilities of Madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-Bis(2-methoxy-4-nitro-5- sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay.

Authors:  Abdalla O A Ahmed; Wendy W J van de Sande; Wim van Vianen; Alex van Belkum; Ahmed H Fahal; Henri A Verbrugh; Irma A J M Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.